The use of  cannabis as a therapeutic agent for various health-related conditions has been nicely documented. Nonetheless, clinical trials in sufferers with Parkinson illness (PD) have yielded conflicting benefits. The aim of the present open-label observational study was to assess the clinical impact of  cannabis on motor and non-motor symptoms of PD.


Twenty-two sufferers with PD attending the motor disorder clinic of a tertiary health-related center in 2011 to 2012 had been evaluated at baseline and 30 minutes right after smoking  cannabis using the following battery: Unified Parkinson Illness Rating Scale, visual analog scale, present discomfort intensity scale, Brief-Type McGill Discomfort Questionnaire, as nicely as Healthcare Cannabis Survey National Drug and Alcohol Investigation Center Questionnaire.

Final results:

Imply (SD) total score on the motor Unified Parkinson Illness Rating Scale score enhanced substantially from 33.1 (13.eight) at baseline to 23.two (10.five) after  cannabis consumption (t = five.9 P < .001). Evaluation of certain motor symptoms revealed substantial improvement after remedy in tremor (P < .001), rigidity (P = .004), and bradykinesia (P < .001).


There was also substantial improvement of sleep and discomfort scores. No substantial adverse effects of the drug had been observed. The study suggests that  cannabis might have a spot in the therapeutic armamentarium of PD. Bigger, controlled research are necessary to confirm the benefits.